Amino-acid PET to track tumor response in IDH‑mutant gliomas (APPEAR)
Positron Emission Tomography-based Response Assessment in Isocitrate Dehydrogenase (IDH)-Mutant Gliomas - a Bicentric, Prospective, Observational Study
This project will test whether amino‑acid PET scans can better track tumor activity over time in adults with IDH‑mutant gliomas.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | LMU Klinikum Academic / other |
| Locations | 2 sites (Vienna and 1 other locations) |
| Trial ID | NCT07159607 on ClinicalTrials.gov |
What this trial studies
This is a prospective, bicentric observational effort collecting longitudinal amino‑acid PET and routine MRI data in adults with histologically confirmed IDH‑mutant astrocytoma or oligodendroglioma. Participating sites will perform PET (including FET PET) during standard postoperative care and follow-up, and imaging will be interpreted using PET RANO recommendations alongside MRI/RANO evaluations. The goal is to describe PET signal changes before, during, and after treatment to distinguish true progression from treatment‑related changes. No experimental therapies are given; the study documents imaging and clinical course under usual care.
Who should consider this trial
Good fit: Adults (≥18) with histologically verified IDH‑mutant astrocytoma or oligodendroglioma who are receiving standard postoperative care and will undergo amino‑acid PET as part of routine follow‑up are ideal candidates.
Not a fit: Patients without an IDH‑mutant glioma, those not receiving routine amino‑acid PET scans, or those enrolled in other interventional experimental therapy trials are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this work could help doctors tell true tumor growth from treatment effects and reduce unnecessary interventions.
How similar studies have performed: Amino‑acid PET has shown promise in prior glioma research and PET RANO guidelines exist, but well‑annotated longitudinal data specifically in IDH‑mutant gliomas remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years * Histologically verified diffuse IDH-mutant glioma (astrocytoma, oligodendroglioma) of any grade as defined in the WHO classification of tumors of the central nervous system * Postoperative treatment according to current standard of care at the time of study inclusion * Performance of amino acid PET as part of clinical routine Exclusion Criteria: * Inclusion in another clinical trial/investigational study involving an experimental therapy or study medication * Inclusion criteria not met
Where this trial is running
Vienna and 1 other locations
- Medical University of Vienna — Vienna, Austria (Recruiting)
- LMU Hospital — Munich, Bavaria, Germany (Recruiting)
Study contacts
- Principal investigator: Nathalie L Albert, Prof. Dr. med. — LMU Klinikum München
- Study coordinator: Nathalie L Albert, Prof. Dr. med
- Email: Nathalie.Albert@med-uni-muenchen.de
- Phone: +4989440074646
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.